Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: International Murex

This article was originally published in The Gray Sheet

Executive Summary

International Murex: Launches five new rapid diagnostic test kits to U.S. clinical reference and hospital laboratories. The company says that the five products, recently cleared by FDA, include kits to "assist in the detection of antibodies to: infectious mononucleosis, group A streptococcus [and] rheumatoid arthritis (two tests)," as well as a test to detect C-reactive protein. The kits, which can provide both qualitative and semiqualitative results, "require no instrumentation," provide results "between 2 and 10 minutes" and "are all equipped with disposable slides that minimize the risk of contamination." The combined market for the new test kits is about $20 mil., Murex estimates...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004715

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel